We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results:1-10 of 783

Judgment on public procurement puts parallel importers at a disadvantage
  • Advokatfirman Lindahl
  • Sweden
  • October 17 2018

The Stockholm Administrative Court recently ruled that the obligation on tenderers of public procurements of medicinal products to have routines which

Celltrion’s and Hospira’s Production of Infliximab Biosimilars Does Not Infringe Remicide-Related Patent
  • Rothwell, Figg, Ernst & Manbeck, PC
  • USA
  • August 20 2018

In a 104-page ruling, U.S. District Judge Mark L. Wolf granted summary judgment in favor of Celltrion and Hospira, finding that a doctrine of

Methods of Treatment Survive Another 101 Challenge - Pernix Ireland Pain DAC v. Alvogen Malta Operations Ltd.
  • K&L Gates
  • USA
  • May 31 2018

On May 15, in Pernix Ireland Pain DAC v. Alvogen Malta Operations Ltd., the U.S. District Court for the District of Delaware upheld two sets of

Article 3 (a) of Regulation (EC) 4692009 : What is the meaning of “protected by a basic patent”
  • European Union, France
  • May 29 2018

By judgment of May 25th, 2018, the Paris Court of First Instance nullified the SPC on the combination of "tenofovir disoproxil and its salts, hydrates

USPTO Says Overlapping Range In Prior Art Insufficient to Invalidate Method of Treatment Patent
  • Dechert LLP
  • USA
  • April 13 2018

Pharmaceutical patents frequently claim treatment methods that utilize a range of amounts or concentrations for the active ingredient or excipients

Rituxan Patent Spared by Failure to Establish Product Label as “Printed Publication”
  • Marshall Gerstein & Borun LLP
  • USA
  • March 26 2018

A patent relating to a method of treating rheumatoid arthritis using rituximab recently survived its fourth IPR challenge. Celltrion, Inc. v. Biogen

  • Marshall Gerstein & Borun LLP
  • USA
  • February 21 2018

In re Janssen Biotech, Inc., Appeal 2017-1257 (Fed. Cir. Jan. 23, 2018), is a cautionary tale concerning patents protecting a blockbuster drug

California Passes Two Drug Pricing Transparency Laws
  • Quarles & Brady LLP
  • USA
  • November 20 2017

Last month, California Governor Jerry Brown signed two new bills aimed at curtailing rising prescription drug costs, joining other states like

CMS Releases 2018 MACRA Final Rule
  • Holland & Knight LLP
  • USA
  • November 10 2017

The Centers for Medicare & Medicaid Services (CMS) on Nov. 2, 2017, posted the CY 2018 Quality Payment Program (QPP) Final Rule. CMS finalized

Post-Grant Amendments from Method of Treatment to Swiss-Style - The Singapore Position
  • Mirandah Asia
  • Singapore
  • August 17 2017

In the landmark case of Warner-Lambert Company LLC v Novartis (Singapore) Pte Ltd 2017 SGCA 45, the Singapore Court of Appeal explored, inte